Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
February 7th 2022Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Read More
Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL
March 13th 2019William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel therapies in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More
Dr. Wierda on Treatment of Relapsed/Refractory CLL
March 7th 2019William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.
Read More